🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,80 EUR

Máx. histórico

912,40

64 días

Caída desde máximo

-10,59%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,03%

Cierre anterior

815,60

Rango de hoy

788,80 – 815,80

Volumen hoy

102.849

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,83 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
1.005,32 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
11/05/2017 16,50 16,54 15,61 15,75 -4,55% 5,64% 7.084
10/05/2017 16,55 16,59 16,31 16,50 +0,61% 1,69% 5.176
09/05/2017 16,62 16,62 16,40 16,40 -0,67% 1,32% 2.183
08/05/2017 16,70 16,70 16,50 16,51 -0,48% 1,20% 14.619
05/05/2017 16,50 16,63 16,50 16,59 +0,55% 0,79% 4.808
04/05/2017 16,70 16,70 16,50 16,50 -1,20% 1,20% 2.575
03/05/2017 16,55 16,70 16,55 16,70 +0,12% 0,91% 9.367
02/05/2017 16,69 16,69 16,49 16,68 +0,42% 1,20% 9.151
28/04/2017 16,62 16,62 16,41 16,61 -0,24% 1,26% 10.549
27/04/2017 16,60 16,65 16,53 16,65 +0,00% 0,72% 2.388
26/04/2017 16,65 16,65 16,57 16,65 +0,12% 0,48% 2.088
25/04/2017 16,74 16,75 16,55 16,63 -0,12% 1,19% 6.192
24/04/2017 16,65 16,75 16,52 16,65 +0,91% 1,38% 14.910
21/04/2017 16,68 16,68 16,49 16,50 -1,08% 1,14% 5.426
20/04/2017 16,68 16,68 16,57 16,68 +0,24% 0,66% 3.610
19/04/2017 16,42 16,65 16,42 16,64 +1,28% 1,40% 10.115
18/04/2017 16,65 16,65 16,43 16,43 +0,06% 1,32% 4.256
13/04/2017 16,45 16,50 16,42 16,42 +0,00% 0,49% 3.692
12/04/2017 16,48 16,65 16,40 16,42 -0,30% 1,52% 4.573
11/04/2017 16,64 16,64 16,30 16,47 +0,43% 2,04% 5.294
10/04/2017 16,45 16,52 16,38 16,40 +0,06% 0,85% 815
07/04/2017 16,42 16,50 16,30 16,39 -0,67% 1,22% 1.304
06/04/2017 16,59 16,59 16,32 16,50 -0,12% 1,63% 1.390
05/04/2017 16,64 16,64 16,22 16,52 -0,24% 2,52% 2.576
04/04/2017 16,31 16,65 16,31 16,56 +0,06% 2,08% 38.815
03/04/2017 16,55 16,55 16,32 16,55 +0,00% 1,39% 19.134
31/03/2017 16,55 16,55 16,22 16,55 +0,06% 1,99% 5.480
30/03/2017 16,29 16,63 16,29 16,54 +1,53% 2,09% 3.419
29/03/2017 16,28 16,29 16,19 16,29 +0,74% 0,61% 2.782
28/03/2017 16,55 16,55 16,11 16,17 -1,64% 2,66% 5.451